SPHK2 and hepatocellular carcinoma: These findings highlight that SphK2 is not only an independent target for HCC treatment but also an important combinatorial target to optimize existing therapies (such as sorafenib and regorafenib), with its clinical translational value urgently requiring validation through subsequent studies.